A subset of patients had low cognitive scores at baseline and follow-up.
Cognitive dysfunction may be associated with neuromyelitis optica spectrum disorder (NMOSD) with aquaporin-4 antibodies (AQP4+), but most studies of the association have been small. Investigators retrospectively evaluated 219 AQP4+ patients followed longitudinally in the Collaborative International Research in Clinical and Longitudinal Experience Study (CIRCLES) in NMOSD.
Based on the Montreal Cognitive Assessment (MoCA) at baseline, 29% were classified as having mild cognitive dysfunction and 5% as having moderate dysfunction. Domains most affected were language and verbal recall. During 11.8 months of follow-up, longitudinal MoCA scores worsened in 30%.
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)